Advice

Recommended for restricted use within NHS Scotland.

RECOMMENDATION.

Telmisartan / hydrochlorothiazide (MicardisPlus®) has efficacy similar to the antihypertensive effects of the individual constituents added together in the treatment of essential hypertension. No increased costs are associated with this product compared with telmisartan (Micardis®) alone. Angiotensin II receptor antagonists are an alternative to ACE inhibitors where these are not tolerated.

Download detailed advice41KB (PDF)

Download

Medicine details

Medicine name:
Telmisartan/hydrochlorothiazide (MicardisPlus®)
SMC ID:
39/03
Indication:
Essential hypertension
Pharmaceutical company
Boehringer Ingelheim Ltd
BNF chapter
Cardiovascular system
Submission type
Full
Status
Restricted
Date advice published
09 May 2003